U.S. pharma big copyright scrapped two experimental weight loss products final year—a after-daily capsule, lotiglipron, on account of elevated liver enzymes and also a 2 times-day by day tablet, danuglipron, as a result of robust Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Perform and win” while